Loading
A phase 2/3 trial of Izalontamab brengitecan, Carboplatin, Cisplatin in non-small-cell lung cancer and small-cell lung cancer, run by Bristol-Myers Squibb, now recruiting.
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01) is a phase 2/3 interventional study registered as NCT07100080 by Bristol-Myers Squibb, with 500 participants planned, started 2025-11-05 and due to reach its primary completion in 2028-12-15. Interventions recorded: Iza-bren, Carboplatin, Cisplatin, Pemetrexed. Conditions listed: Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Izalontamab brengitecan, Pemetrexed, Bristol Myers Squibb, EGFR-mutated non-small-cell lung cancer.
Shares Izalontamab brengitecan, Pemetrexed, EGFR-mutated non-small-cell lung cancer, Cisplatin.
Shares Pemetrexed, EGFR-mutated non-small-cell lung cancer, Cisplatin, Carboplatin.
Shares Izalontamab brengitecan, Pemetrexed, EGFR-mutated non-small-cell lung cancer, Small-cell lung cancer.
Shares Pemetrexed, Bristol Myers Squibb, Cisplatin, Carboplatin.
Shares Pemetrexed, EGFR-mutated non-small-cell lung cancer, Cisplatin, Carboplatin.
Shares Pemetrexed, Bristol Myers Squibb, Cisplatin, Carboplatin.
Shares Pemetrexed, Bristol Myers Squibb, Cisplatin, Carboplatin.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/